Mammary Cell News Volume 6.48 | Dec 11 2014

Resolving Cancer-Stroma Interfacial Signaling and Interventions with Micropatterned Tumor-Stromal Assays
A micropatterned tumor-stromal assay revealed a spatial distribution of phenotypes in concordance with human ​estrogen receptor-positive (ER⁺) breast cancer samples, and heterogeneous drug activity relative to the tumor-stroma interface. Specifically, an unknown mechanism of ​reversine is shown in targeting tumor-stromal interfacial interactions using ​ER⁺ MCF-7 breast cancer and bone marrow-derived stromal cells. [Nat Commun] Abstract

HSP90 Empowers Evolution of Resistance to Hormonal Therapy in Human Breast Cancer Models
Guided by their previous work in pathogenic fungi, in which very modest heat shock protein 90 (HSP90) inhibition impairs resistance to mechanistically diverse antifungals, researchers examined the effect of similarly modest HSP90 inhibition on the emergence of resistance to antiestrogens in breast cancer models. [Proc Natl Acad Sci USA] Abstract | Press Release

Hematopoietic PBX-Interacting Protein (HPIP) Is Over Expressed in Breast Infiltrative Ductal Carcinoma and Regulates Cell Adhesion and Migration through Modulation of Focal Adhesion Dynamics
Investigators show that HPIP expression is associated with stages of breast cancer where cell dissemination results in poor patient outcome. They found a novel association of HPIP with focal adhesion kinase regulating focal adhesion dynamics. [Oncogene] Abstract

Targeting Type Iγ Phosphatidylinositol Phosphate Kinase Inhibits Breast Cancer Metastasis
Researchers report that type Iγ phosphatidylinositol phosphate kinase (PIPKIγ) is vital for breast cancer metastasis. Y639 of PIPKIγ can be phosphorylated by stimulation of EGF and hepatocyte growth factor, two promoting factors for breast cancer progression. [Oncogene] Abstract

Neuregulin 1-Activated ERBB4 Interacts with YAP to Induce Hippo Pathway Target Genes and Promote Cell Migration
Researchers found that ERBB4 activated the transcriptional coactivator YAP, which promotes organ and tissue growth and is inhibited by the Hippo tumor-suppressor pathway. Overexpressing ERBB4 in cultured mammary epithelial cells or adding the ERBB4 ligand neuregulin 1 to breast cancer cell cultures promoted the expression of genes regulated by YAP, such as CTGF. [Sci Signal] Abstract

ANG4043, a Novel Brain-Penetrant Peptide-mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Scientists demonstrate that a conjugate between Angiopep-2 and an anti-HER2 monoclonal antibody (mAb) results in a new chemical entity, ANG4043, which retains in vitro binding affinity for the HER2 receptor and antiproliferative potency against HER2-positive BT-474 breast ductal carcinoma cells. [Mol Cancer Ther] Abstract | Press Release

Xanthohumol Suppresses Estrogen-Signaling in Breast Cancer through the Inhibition of BIG3-PHB2 Interactions
The authors focus on whether xanthohumol directly binds to the tumor suppressor protein prohibitin 2 (PHB2), forming a novel natural antitumor compound targeting the BIG3-PHB2 complex and acting as a pivotal modulator of E2/ERα signaling in breast cancer cells. [Sci Rep] Full Article

Unraveling the Chromosome 17 Patterns of FISH in Interphase Nuclei: An In-Depth Analysis of the HER2 Amplicon and Chromosome 17 Centromere by Karyotyping, FISH and M-FISH in Breast Cancer Cells
Investigators sought to elucidate the chromosome 17 centromere and HER2 fluorescence in situ hybridization (FISH) patterns of interphase nuclei by evaluating Chr17 rearrangements in metaphases of nine breast cancer cell lines and a primary culture from a triple negative breast carcinoma by using G-banding, FISH and multicolor-FISH (M-FISH). [BMC Cancer] Abstract | Full Article

CLINICAL RESEARCH

Weekly Docetaxel vs CMF as Adjuvant Chemotherapy for Older Women with Early Breast Cancer: Final Results of the Randomized Phase III ELDA Trial
Investigators tested whether weekly docetaxel is more effective than standard chemotherapy. They performed a multicenter, randomized Phase III study. Women aged 65 to 79, operated for breast cancer, with average to high risk of recurrence, were allocated to CMF or docetaxel every four weeks, for four or six cycles according to hormone-receptor status. [Ann Oncol] Abstract

Neoadjuvant Treatment with Docetaxel plus Lapatinib, Trastuzumab, or Both followed by an Anthracycline Based Chemotherapy in HER2-Positive Breast Cancer: Results of the Randomized Phase II EORTC 10054 Study
Neoadjuvant trials conducted using a double HER2-blockade with lapatinib and trastuzumab, combined with different paclitaxel-containing chemotherapy regimens, have shown high pathological complete response rates, but at the cost of important toxicity. This trial assessed the toxicity and activity of the combination of docetaxel with lapatinib and trastuzumab. [Ann Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

New Drug Combination for Advanced Breast Cancer Delays Disease Progression
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center Phase II trial. [Press release from Yale University discussing research presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

Platinum Agent Combination Treatment for Triple-Negative Breast Cancer Well Tolerated in Phase II Clinical Trial
Research shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. [Press release from Rutgers Cancer Institute of New Jersey discussing research presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2⁺ Breast Cancer Patients
A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer—the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy—appears irrelevant when trastuzumab is used. [Press release from Mayo Clinic discussing research presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

Pathway that Degrades Holiday Turkey Fuels Metastasis of Triple Negative Breast Cancer
Researchers show that triple negative breast cancer cells process tryptophan to promote survival while traveling through the body in order to seed new tumor sites. [Press release from University of Colorado Cancer Center discussing research presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

James Ingle of Mayo Clinic Recognized for Breast Cancer Research
James Ingle, M.D., an internationally recognized breast cancer expert, received the 2014 William L. McGuire Memorial Lecture Award at the 2014 San Antonio Breast Cancer Symposium. [Mayo Clinic] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Associate or Full Professor – Surgical Breast Pathology (Perelman School of Medicine)

NEW Postdoctoral Position – Breast Cancer Metastasis (Northwestern University)

Postdoctoral Position – Breast Cancer Biology (Baylor College of Medicine)

Postdoctoral Fellow – Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Professor – Breast/Abdominal Surgery or Gynecology (Fudan University Shanghai Cancer Center)

Postdoctoral Fellow – Breast Cancer (University of Texas Health Science Center at San Antonio)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.